Emerging treatments
Anti-thymocyte globulin and haematopoietic stem cell transplant
Anti-thymocyte globulin is usually used for acute transplant rejection. It is a polyclonal antibody that depletes CD4 lymphocytes by binding to surface antigens. Preliminary data from small studies indicate benefit of autologous non-myeloablative haematopoietic stem cell transplant and anti-thymocyte globulin in refractory systemic vasculitis.[71][72]
Alemtuzumab
Identifying molecular targets in non-systemic vasculitic neuropathy is an active area of research. One study showed that CD52 is found in nerve biopsies of patients with non-systemic vasculitic neuropathy.[73] Therefore, alemtuzumab, an anti-CD52 monoclonal antibody, may be a potential pharmacological therapy for non-systemic vasculitic neuropathy.
Use of this content is subject to our disclaimer